Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 273

  • Filters activated: Toxicology. Clear all to show 384 items.
1.

Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial.

Wu J, Duan L, Zhang L, Sun Z, Fu X, Li X, Li L, Wang X, Zhang X, Li Z, Yu H, Chang Y, Nan F, Yan J, Tian L, Wang X, Zhang M.

J Neurooncol. 2018 Nov;140(2):427-434. doi: 10.1007/s11060-018-2970-x. Epub 2018 Aug 14.

2.

High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.

Marinelli A, Lamberti G, Cerbone L, Cordua N, Buonerba C, Peluso G, Di Lorenzo G, De Placido S.

Medicine (Baltimore). 2018 Jul;97(27):e11254. doi: 10.1097/MD.0000000000011254.

3.

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).

Guida M, Tommasi S, Strippoli S, Natalicchio MI, De Summa S, Pinto R, Cramarossa A, Albano A, Pisconti S, Aieta M, Ridolfi R, Azzariti A, Guida G, Lorusso V, Colucci G.

BMC Cancer. 2018 May 10;18(1):552. doi: 10.1186/s12885-018-4479-2.

4.

Impressive tissue regeneration of severe oral mucositis post stem cell transplantation using cord blood platelet gel.

Piccin A, Rebulla P, Pupella S, Tagnin M, Marano G, Di Pierro AM, Santodirocco M, Di Mauro L, Beqiri L, Kob M, Primerano M, Casini M, Billio A, Eisendle K, Fontanella F.

Transfusion. 2017 Sep;57(9):2220-2224. doi: 10.1111/trf.14205. Epub 2017 Jun 27.

PMID:
28656652
5.

Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling.

Nikolova T, Roos WP, Krämer OH, Strik HM, Kaina B.

Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):29-39. doi: 10.1016/j.bbcan.2017.01.004. Epub 2017 Jan 29. Review.

PMID:
28143714
6.

Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.

Gammaitoni L, Giraudo L, Macagno M, Leuci V, Mesiano G, Rotolo R, Sassi F, Sanlorenzo M, Zaccagna A, Pisacane A, Senetta R, Cangemi M, Cattaneo G, Martin V, Coha V, Gallo S, Pignochino Y, Sapino A, Grignani G, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2017 May 1;23(9):2277-2288. doi: 10.1158/1078-0432.CCR-16-1524. Epub 2016 Nov 4.

7.

Targeting Homologous Recombination by Pharmacological Inhibitors Enhances the Killing Response of Glioblastoma Cells Treated with Alkylating Drugs.

Berte N, Piée-Staffa A, Piecha N, Wang M, Borgmann K, Kaina B, Nikolova T.

Mol Cancer Ther. 2016 Nov;15(11):2665-2678. Epub 2016 Jul 29.

8.

Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.

Lombardi G, Bellu L, Pambuku A, Della Puppa A, Fiduccia P, Farina M, D'Avella D, Zagonel V.

J Neurooncol. 2016 Jul;128(3):481-6. doi: 10.1007/s11060-016-2136-7. Epub 2016 May 11.

PMID:
27165580
9.

Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.

Vouk K, Benter U, Amonkar MM, Marocco A, Stapelkamp C, Pfersch S, Benjamin L.

J Med Econ. 2016 Sep;19(9):900-12. doi: 10.1080/13696998.2016.1184155. Epub 2016 May 30.

PMID:
27123564
10.

Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.

Middleton MR, Dalle S, Claveau J, Mut P, Hallmeyer S, Plantin P, Highley M, Kotapati S, Le TK, Brokaw J, Abernethy AP.

Cancer Med. 2016 Jul;5(7):1436-43. doi: 10.1002/cam4.717. Epub 2016 Apr 26.

11.

Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.

Krumm A, Barckhausen C, Kücük P, Tomaszowski KH, Loquai C, Fahrer J, Krämer OH, Kaina B, Roos WP.

Cancer Res. 2016 May 15;76(10):3067-77. doi: 10.1158/0008-5472.CAN-15-2680. Epub 2016 Mar 15.

12.

Use of closed systems in the Hospital Pharmacy.

Forte Pérez-Minayo M, Castillo Bazán E, Hernández Segurado M, Arias Moya MÁ, Pelegrín Torres P, Bécares Martínez FJ.

Farm Hosp. 2016 Mar 1;40(2):102-10. doi: 10.7399/fh.2016.40.2.9994.

13.

Nitrosoureas in the Management of Malignant Gliomas.

Brandes AA, Bartolotti M, Tosoni A, Franceschi E.

Curr Neurol Neurosci Rep. 2016 Feb;16(2):13. doi: 10.1007/s11910-015-0611-8. Review.

PMID:
26750128
14.

GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.

Pérez-Segura P, Manneh R, Ceballos I, García A, Benavides M, Fuster J, Vaz MA, Cano JM, Berros JP, Covela M, Moreno V, Quintanar T, García Bueno JM, Fernández I, Sepúlveda J.

Clin Transl Oncol. 2016 Aug;18(8):805-12. doi: 10.1007/s12094-015-1444-2. Epub 2015 Nov 5.

PMID:
26542177
15.

Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.

Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A.

Br J Haematol. 2016 Jan;172(1):111-21. doi: 10.1111/bjh.13803. Epub 2015 Oct 12.

17.

Retrospective analysis of bevacizumab in combination with fotemustine in chinese patients with recurrent glioblastoma multiforme.

Liu Z, Zhang G, Zhu L, Wang J, Liu D, Lian L, Liu J, Lai T, Zhuang X.

Biomed Res Int. 2015;2015:723612. doi: 10.1155/2015/723612. Epub 2015 Feb 18.

18.

B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.

Roos WP, Quiros S, Krumm A, Merz S, Switzeny OJ, Christmann M, Loquai C, Kaina B.

Oncotarget. 2014 Dec 30;5(24):12607-20.

19.

Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.

Porru M, Zappavigna S, Salzano G, Luce A, Stoppacciaro A, Balestrieri ML, Artuso S, Lusa S, De Rosa G, Leonetti C, Caraglia M.

Oncotarget. 2014 Nov 15;5(21):10446-59.

20.

Translesion polymerase η is upregulated by cancer therapeutics and confers anticancer drug resistance.

Tomicic MT, Aasland D, Naumann SC, Meise R, Barckhausen C, Kaina B, Christmann M.

Cancer Res. 2014 Oct 1;74(19):5585-96. doi: 10.1158/0008-5472.CAN-14-0953. Epub 2014 Aug 14.

Supplemental Content

Loading ...
Support Center